Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Borraginol is a comprehensive line of hemorrhoid treatments developed and marketed by Amato Pharmaceutical Products. Originally developed at Kyoto University Hospital and launched in 1921, it is a leading over-the-counter (OTC) brand in Japan for the relief of pain, bleeding, swelling, and itching associated with hemorrhoids and anal fissures. The product line is divided into the **Borraginol A** series, which includes the corticosteroid prednisolone acetate for anti-inflammatory action, and the steroid-free **Borraginol M** series. Both series typically contain lidocaine (local anesthetic), allantoin (wound healing), and vitamin E acetate (blood circulation improvement). Additionally, the brand includes **Borraginol EP Oral**, an internal medication containing herbal extracts like Moutan cortex and Rosskastanien to address hemorrhoidal symptoms from within.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Borraginol.